We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+5.08%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.49B
AUM Growth
+$37.4M
Cap. Flow
-$505M
Cap. Flow %
-20.29%
Top 10 Hldgs %
34.18%
Holding
156
New
33
Increased
30
Reduced
32
Closed
28

Top Buys

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$84.9M
2
EHTH icon
eHealth
EHTH
+$41.7M
3
KERX
Keryx Biopharmaceuticals Inc
KERX
+$35.2M
4
AGN
Allergan Inc
AGN
+$34M
5
ITMN
INTERMUNE INC
ITMN
+$26.9M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$87.6M
2
LH icon
Labcorp
LH
+$56.3M
3
MRK icon
Merck
MRK
+$27.1M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$26.4M
5
DGX icon
Quest Diagnostics
DGX
+$25.5M

Sector Composition

Rank Sector Weight
1 Healthcare 42.33%
2 Financials 2.57%
3 Technology 1.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
126
Merck
MRK
$307B
– –
-500,106
Closed -$27.1M
NGNE icon
127
Neurogene
NGNE
$745M
– –
-3,119
Closed -$794K
PTCT icon
128
PTC Therapeutics
PTCT
$6.47B
– –
-317,530
Closed -$8.3M
QURE icon
129
uniQure
QURE
$2.73B
– –
-350,000
Closed -$5.45M
REGN icon
130
Regeneron Pharmaceuticals
REGN
$70.5B
– –
-4,799
Closed -$1.44M
SNDA icon
131
Sonida Senior Living
SNDA
$1.92B
– –
-20,539
Closed -$8.01M
TNXP icon
132
Tonix Pharmaceuticals
TNXP
$175M
– –
0
– -$2.54M
VTRS icon
133
Viatris
VTRS
$19.8B
– –
-17,500
Closed -$855K
XOMA
134
CALL
DELISTED
Xoma
XOMA
– –
-50,000
Closed -$5.21M
ITCI
135
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-171,437
Closed -$3.12M
NVDQ
136
DELISTED
Novadaq Technologies Inc.
NVDQ
– –
-10,000
Closed -$223K
ELOS
137
DELISTED
Syneron Medical Ltd
ELOS
– –
-34,518
Closed -$430K
ZGNX
138
DELISTED
Zogenix, Inc.
ZGNX
– –
-771,851
Closed -$17.6M
GEVA
139
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-317,678
Closed -$26.4M
AUXL
140
PUT
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
– –
-250,000
Closed -$6.79M
FURX
141
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
– –
-13,340
Closed -$1.16M
MDVN
142
DELISTED
MEDIVATION, INC.
MDVN
– –
-25,000
Closed -$805K
2 3 4 5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2014 Portfolio in Review

As of Q2 2014, Deerfield Management held 156 positions worth $2.49B, up 1.5% from $2.45B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Deerfield Management withdrew a net $505M in Q2 2014, closing 28 positions and reducing 32 holdings. Its most notable exit was Merck, an estimated $27.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 44% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK worth $23.1M.

  • Deerfield Management's largest Q2 2014 buy was TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK: 1,482,666 shares worth $23.1M.
  • Deerfield Management added most to AUXILIUM PHARAMCEUTICALS INC in Q2 2014, an estimated $84.9M increase.
  • Deerfield Management's biggest Q2 2014 reduction was QUESTCOR PHARMA INC, cutting an estimated $87.6M.
  • Deerfield Management fully exited Merck in Q2 2014, selling an estimated $27.1M.
  • Deerfield Management's ten largest holdings make up 34% of its $2.49B portfolio in Q2 2014.
  • Deerfield Management opened 33 new positions and closed 28 in Q2 2014.
  • Deerfield Management's portfolio value rose 1.5% quarter-over-quarter to $2.49B.

Based on Deerfield Management's 13F filing for Q2 2014, filed 14 Aug 2014.